APhA Expresses Disappointment Over Change in Hepatitis B Vaccine Recommendations

Concerns Raised by APhA over Hepatitis B Vaccine Recommendations

In a recent announcement, the American Pharmacists Association (APhA) articulated its significant discontent regarding a decision made by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices. The committee voted to withdraw its universal recommendation for administering the hepatitis B vaccine at birth for infants born in the United States. This reversal is seen as damaging to public health initiatives that have successfully been in place since their initiation in 1991.

The universal birth-dose recommendation has played a pivotal role in drastically reducing acute hepatitis B virus (HBV) infections among infants and young children, effectively preventing numerous instances of chronic HBV infections in these vulnerable populations. The hepatitis B vaccine is acknowledged as safe and effective, deemed the most reliable approach to stave off chronic HBV infections.

The recent CDC decision has prompted ApHA to express their alarm, citing that even infants born to non-HBV carrier mothers are at a substantial risk due to potential exposure within their own homes. This could arise from infected household members, caregivers, or even through simple interactions like sharing personal items. It substantiates the rationale for maintaining a universal vaccination policy at birth.

Brigid Groves, PharmD, MS, who holds the position of vice president of professional affairs at APhA, emphasized the longstanding contribution of pharmacists in the combat against disease transmission via vaccinations, including those for hepatitis B. She affirmed their unwavering commitment to public health and strongly called for the preservation of the current immunization standards. The consensus in the health community is clear: the hepatitis B birth dose saves lives and there appears to be no new evidence supporting the withdrawal of such essential healthcare measures.

What’s disconcerting is that a newborn infected with HBV has about a 90% chance of developing into a chronic carrier, and the dire consequences of such infections cannot be overstated. One in four infants infected at birth are likely to succumb to liver failure or liver cancer linked to the infection. Furthermore, those who develop HBV at a young age face an alarming 20% to 50% chance of sustaining a lifelong chronic infection, alongside the heavy burdens – financially and medically – that come with treatment of these severe conditions.

In light of these developments, APhA has reasserted its stance on the essentiality of preserving the established immunization schedule, citing evidence that underpins the necessity for the HepB birth dose which has consistently been recognized for its safety and efficacy.

APhA also acknowledged that hepatitis B vaccination remains crucial into adulthood. The committee continues to uphold that adults aged 19-59 years, those aged 60 and above with underlying risk factors, and any adult who requests vaccination, should receive the HBV vaccine series. The organization highlighted the accessibility and safety of hepatitis B vaccines, which are also covered by various insurance plans.

Looking forward, APhA pledges to uphold the advocacy for immunization policies grounded in scientific evidence while prioritizing the health and safety of patients across the nation.

About APhA

The American Pharmacists Association represents the collective interests of pharmacy professionals. Based in Washington, DC, APhA is committed to supporting pharmacists, student pharmacists, and pharmacy technicians in optimizing medication use and enhancing patient health outcomes. Through advocacy, educational resources, and collaborative opportunities, APhA seeks to influence national guidelines and reinforce the pharmacy profession’s role in patient care. For more information, please visit www.pharmacist.com.